New bioMérieux Assay Detects Broadest Range Of HIV-1 Load Levels
This article was originally published in The Gray Sheet
A "real-time" version of bioMérieux' NucliSens nucleic acid diagnostic system, the NucliSens EasyQ,will be available in the U.S. by the end of 2002, pending FDA approval of a PMA supplement, according to bioMérieux
You may also be interested in...
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.